After-Hours Action: What's Going On With Guardant Health, Exact Sciences Shares? - Exact Sciences (NASDAQ:EXAS)Benzinga • 12/15/22
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancerBusiness Wire • 12/15/22
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast CancerBusiness Wire • 12/08/22
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer PatientsBusiness Wire • 12/01/22
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022Business Wire • 10/10/22
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients SoonerBusiness Wire • 09/09/22
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patientsBusiness Wire • 09/06/22
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology TherapeuticsBusiness Wire • 08/31/22
Guardant Health to Participate in the Morgan Stanley Global Healthcare ConferenceBusiness Wire • 08/29/22
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung CancersBusiness Wire • 08/15/22
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca's ENHERTU® for Treatment of NSCLC Patients With Activating HER2 MutationsBusiness Wire • 08/12/22
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit ConferenceBusiness Wire • 08/08/22
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung CancerBusiness Wire • 08/08/22
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung CancerBusiness Wire • 08/05/22
Guardant Health, Inc. (GH) Management on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22